How Long Does Postherpetic Neuralgia Last?

Most cases of postherpetic neuralgia resolve within a year, though the condition can linger far longer in a minority of patients. In a prospective study with long-term follow-up, about one in thirty shingles patients still reported some pain at twelve months, and a handful of those continued to experience discomfort years later. The duration depends heavily on age, the severity of the initial shingles episode, and how quickly treatment begins, which means the honest answer is a range rather than a single number.

What Counts as Postherpetic Neuralgia

Postherpetic neuralgia, or PHN, is pain that persists after a shingles rash has healed. The most widely used clinical definition sets the cutoff at three months from the onset of the rash.¹ Some researchers have used shorter windows, like one month or six weeks, which is part of why prevalence numbers vary from study to study. An infrared thermographic imaging study found that the biologically meaningful transition point between acute zoster pain and true PHN aligns well with the twelve-week mark, lending support to the three-month convention.² This distinction matters because the pain many people feel in the first few weeks after shingles is still part of the acute episode and usually fades on its own. PHN is what remains after that window closes.

The Typical Timeline

The good news is that the prevalence of lingering pain drops steadily with time. A study following shingles patients in East London found that about 30% still had pain at six weeks, roughly 27% at twelve weeks, about 16% at six months, and 9% at one year.³ Those numbers include patients of all ages and severity levels, so they paint a broad picture of how the pain thins out over time.

A large prospective study with years of follow-up found a similar pattern but added important detail about severity. Among patients under sixty, the risk of PHN at three months was under 2%, and whatever pain existed was mild. In patients sixty and older, the risk was higher but the pain was still usually mild or moderate. By twelve months, no patient in that cohort reported severe pain. About 3% still had mild or moderate pain at the one-year mark. Of those, roughly half became pain-free within two to seven years. A small number, however, were still reporting mild to moderate pain after more than seven years of follow-up.⁴

When researchers have focused specifically on patients who already have established PHN, the median duration of pain from rash onset has been estimated at about nine months, with women trending longer than men (a median of twelve months versus six).⁵ But the range in that same study stretched from six months to over twelve years, which captures why this question frustrates people looking for a tidy answer. The typical course is months, not decades. But “typical” does not describe everyone.

Who Is More Likely to Have Longer-Lasting Pain

Age is the single strongest predictor. The risk of developing PHN in the first place climbs steeply after fifty, with the sharpest increase between ages fifty and seventy-nine. One large cohort study calculated that for every ten-year increase in age, the odds of PHN roughly doubled.⁶ Age does not just raise the risk of getting PHN; it also tends to extend its duration and make it harder to treat.

Beyond age, several other factors consistently show up across studies:

Acute pain severity: The worse the pain during the active shingles rash, the more likely it is to persist afterward. Multiple prospective studies have confirmed this link.⁷
Rash severity: A more extensive or severe rash is associated with both a higher risk and a longer course of PHN.⁷
Prodromal symptoms: Pain or tingling before the rash appears signals a more aggressive viral reactivation and predicts prolonged pain. When prodromal symptoms combine with older age and severe acute pain, the risk of persistent pain climbs substantially.⁸
Functional status before shingles: People who already had limitations in performing daily activities before their shingles episode were more likely to develop PHN, suggesting that overall health resilience plays a role.⁹

The interaction between these factors matters. Having two or more risk factors at the same time significantly increases the chances of prolonged pain compared to having any single factor alone.⁸

Why PHN Persists After the Rash Heals

The rash itself is not what causes the lasting pain. PHN is fundamentally a nerve-damage problem. During a shingles episode, the varicella-zoster virus reactivates in nerve cells and spreads along nerve fibers to the skin. In the process, it damages or destroys sensory neurons. The pain that lingers after the skin heals reflects persistent injury to those nerve pathways.¹⁰

Skin biopsies from people with PHN show a loss of the small nerve fibers in the outer layer of skin, and the more severe that loss, the more severe the pain tends to be. At a deeper level, autopsy studies have found atrophy in the dorsal horn of the spinal cord in areas corresponding to the affected skin, showing that the damage is not confined to the periphery.¹¹ When incoming nerve signals from the skin are reduced because the sensory neurons have been destroyed, the central nervous system sometimes ramps up its activity in response. This central sensitization is part of why PHN pain can feel so disproportionate to any visible injury and can involve sensations like burning or electric shocks with no obvious trigger.

Understanding this helps explain why duration varies so much. If nerve damage is mild, regeneration may occur over weeks to months and the pain fades. If the damage is extensive, particularly if it reaches the spinal cord level, recovery is slower and sometimes incomplete.

What PHN Actually Feels Like

PHN is not a single type of pain. People describe it in various ways: a constant burning or aching, sharp stabbing episodes, deep throbbing, or an exquisite sensitivity where even light touch on the affected skin causes pain. That last symptom, called allodynia, is one of the hallmarks. A study tracking sensory changes over time found that people who went on to develop PHN had a larger area of allodynia, more severe allodynia, and greater difficulty detecting warmth and cold compared with those whose pain resolved.¹² While some sensory deficits improved over time, the ability to detect warmth and heat pain did not improve in that cohort, suggesting lasting damage to certain nerve fiber types.

The location of the pain follows the original shingles rash, typically running in a band along one side of the torso, though the face, neck, and limbs can also be affected. Clothing brushing against the skin, bedsheets at night, even a breeze can be enough to trigger a pain flare when allodynia is present. This unpredictability makes PHN particularly disruptive to sleep and daily routine.

The Impact on Everyday Life

PHN goes well beyond physical discomfort. Research consistently shows that it takes a toll across physical, psychological, functional, and social domains. More severe pain correlates with greater interference with daily activities, including the ability to work, exercise, socialize, and maintain normal sleep.¹³ Depression and anxiety are common companions. This is not just anecdotal: a study measuring outcomes of spinal cord stimulation for PHN found that patients’ depression scores and sleep quality at baseline were significant factors in their treatment response, illustrating how tightly pain, mood, and sleep are tangled together in this condition.¹⁴

The financial cost adds another layer of burden. Patients with PHN incur roughly twice the healthcare costs of shingles patients who do not develop PHN.¹⁵ In China, survey data showed that employed individuals with PHN lost the equivalent of thousands of dollars per year in work productivity, and out-of-pocket prescription costs alone accounted for a substantial portion of household spending on the disease.¹⁶ For a condition that may last a year or more, those costs compound.

Treatments That Can Shorten or Ease PHN

There are two separate treatment questions: what you can do during the shingles episode to reduce the risk of PHN developing, and what you can do once PHN has already set in.

Early Antiviral Therapy

Starting antiviral medication within seventy-two hours of the shingles rash appearing can reduce both the severity of the acute episode and the likelihood and duration of PHN, particularly in older adults.¹⁷ ¹⁸ This seventy-two-hour window is why doctors emphasize getting seen quickly when shingles is suspected. Antivirals do not guarantee you will avoid PHN, but they shift the odds meaningfully.

Medications for Established PHN

Once PHN is established, treatment aims to control pain and improve function rather than cure the underlying nerve damage. The most commonly used first-line medications are gabapentin and pregabalin, which work by dampening overactive nerve signaling. Topical lidocaine patches applied directly to the painful area provide localized relief with minimal systemic side effects and are often used alongside oral medications.¹⁹ High-concentration capsaicin patches represent another topical option: a single sixty-minute application can provide significant pain relief lasting up to three months.²⁰ Randomized trials have confirmed the long-term safety and sustained relief of repeat capsaicin patch treatments over a full year.²¹

For patients who do not respond adequately to these first-line options, tricyclic antidepressants like amitriptyline or nortriptyline can be added. A case series of patients aged sixty-six to seventy-one who had failed gabapentinoids, lidocaine, and opioids found that adding a tricyclic antidepressant produced meaningful reductions in pain intensity and improved daily functioning.¹⁹ Opioids are sometimes used for severe, refractory cases, though the risks of long-term opioid therapy make them a last resort.

Interventional Approaches

When medications are not enough, spinal cord stimulation has shown promise. A clinical study found that temporary spinal cord stimulation produced rapid pain reduction and higher patient satisfaction compared to continuous epidural analgesia, while avoiding the side effects of lowered blood pressure and urinary retention that came with the epidural approach.²² Another study found that spinal cord stimulation outperformed nerve block therapy in pain reduction at one month and three months, though the advantage narrowed over longer follow-up. Spinal cord stimulation patients still showed better improvements in sleep, mood, and overall quality of life at six to twelve months.¹⁴ These are not first-line treatments, but they offer a real option for people whose pain has resisted standard therapies.

PHN Involving the Eye

When shingles affects the ophthalmic branch of the trigeminal nerve, the resulting condition is called herpes zoster ophthalmicus, or HZO. PHN following HZO can be particularly problematic because the pain affects the forehead, eyelid, and area around the eye. A randomized trial studying low-dose valacyclovir in people with HZO-related PHN illustrated the mix of patient profiles: roughly a third of participants had chronic disease that had already been present for an extended period, while the remainder had more recent onset.²³ The split between chronic and recent cases was not significantly different between age groups in that study, but the fact that a meaningful proportion of facial PHN had already become chronic underscores that location alone does not determine outcome. The face has dense nerve supply, though, and facial PHN can interfere with vision care and is harder to treat with topical patches due to proximity to the eyes.

The Role of Sex Differences

Several studies hint at differences between men and women, though the evidence is less robust than for age. The one-year follow-up study mentioned earlier found that the median duration of pain from rash onset was twelve months in women versus six months in men, though that difference did not quite reach conventional statistical significance.⁵ Whether women experience PHN for longer because of biological differences in pain processing, hormonal factors, differences in healthcare-seeking behavior, or simply because women in these studies tended to be older is not settled. It is worth being aware of, especially for women over sixty with severe acute shingles pain, since the risk factors stack.

How Common Is PHN in the First Place

Estimates of what fraction of shingles patients go on to develop PHN vary depending on the definition used and the age of the population studied. Commonly cited figures range from about 5% to 20% of all herpes zoster patients.²⁴ Among younger adults, the percentage is at the low end or even below it. Among people over seventy, it can be substantially higher. This range explains why some people hear “PHN is rare” and others hear “PHN is common” — both statements can be true depending on which age group you are talking about.

Vaccination with the recombinant zoster vaccine has dramatically changed this picture for people who receive it before developing shingles. Clinical trials showed the vaccine reduces the risk of shingles itself by more than 90% in adults over fifty, and because PHN almost always follows a shingles episode, preventing shingles effectively prevents PHN. For adults who have not been vaccinated and develop shingles, the risk factors outlined earlier determine where they fall on the PHN probability spectrum.

When You Should Worry About Unusually Long PHN

If your PHN has persisted beyond a year with no sign of improvement, that does not mean it will last forever, but it does suggest the nerve damage was substantial and that passive waiting is unlikely to resolve it. The long-term follow-up data from the BMJ study showed that even among patients who still had pain at one year, some continued to improve over the following years.⁴ Late improvement is possible, but at that stage, working with a pain specialist to optimize your treatment regimen makes more sense than hoping the pain will resolve on its own. Medication combinations, interventional procedures like nerve blocks or spinal cord stimulation, and attention to sleep and mood can all meaningfully reduce the burden even when the underlying nerve damage is permanent.

A useful way to think about the timeline: the steepest drop in pain prevalence happens in the first six months. If you are in those early months of PHN, the odds are genuinely in your favor. After twelve months, improvement still happens but slows. And for the small number of people who reach the multi-year mark with ongoing pain, the goal shifts from cure to management, keeping pain tolerable enough that it does not dominate daily life.

1
PubMed Central. Herpes zoster (shingles) and postherpetic neuralgia
2
PubMed Central. Determining the Definitive Time Criterion for Postherpetic Neuralgia Using Infrared Thermographic Imaging
3
PubMed. A study of shingles and the development of postherpetic neuralgia in East London
4
BMJ. Prevalence of postherpetic neuralgia after a first episode of herpes zoster: prospective study with long term follow up
5
PubMed Central. One-year follow-up of patients with long-lasting post-herpetic neuralgia
6
PubMed Central. Quantification of risk factors for postherpetic neuralgia in herpes zoster patients: A cohort study
7
The Journal of Infectious Diseases. Postherpetic Neuralgia: Impact of Famciclovir, Age, Rash Severity, and Acute Pain in Herpes Zoster Patients
8
The Journal of Infectious Diseases. The Identification of Risk Factors Associated with Persistent Pain following Herpes Zoster
9
PubMed. Predictors of postherpetic neuralgia among patients with herpes zoster: a prospective study
10
The Journal of Pain. The Pathology of Shingles: The Cause of Postherpetic Neuralgia and Itch
11
PubMed Central. Mechanisms of pain and itch caused by herpes zoster (shingles)
12
PubMed. Natural history of sensory function after herpes zoster
13
PubMed Central. The impact of herpes zoster and post-herpetic neuralgia on quality-of-life
14
PubMed Central. Clinical study of short-term spinal cord stimulation for herpes zoster-associated pain
15
Dermatologica Sinica. Clinical and economic burden of herpes zoster and postherpetic neuralgia in patients from the National Skin Centre, Singapore
16
PubMed Central. Patient and economic burdens of postherpetic neuralgia in China
17
PubMed. The role of antivirals in the management of neuropathic pain in the older patient with herpes zoster
18
PubMed. Management of herpes zoster and post-herpetic neuralgia
19
PubMed Central. The Use of Tricyclic Antidepressants for Postherpetic Neuralgia – A Case Series
20
PubMed Central. Tolerability of NGX-4010, a capsaicin 8% dermal patch, following pretreatment with lidocaine 2.5%/prilocaine 2.5% cream in patients with post-herpetic neuralgia
21
Journal of Pain and Symptom Management. Topical Treatment of Peripheral Neuropathic Pain: Applying the Evidence
22
PubMed. Effect of temporary spinal cord stimulation on postherpetic neuralgia in the thoracic nerve area
23
JAMA Network. Low-Dose Valacyclovir for Postherpetic Neuralgia in the Zoster Eye Disease Study: A Randomized Clinical Trial
24
PubMed Central. Acupuncture therapy for treating postherpetic neuralgia: A protocol for an overview of systematic reviews and meta-analysis